GlassScriptPhysician profile
Chenyang Zhan
NPI 1164884060
$6,437.81
in general payments reported to CMS, 2019-2025
10 companies · $4,370 in 2025
The $4,370 reported for 2025 was more than what 84% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $1,468 · 2023: $157 · 2024: $259 · 2025: $4,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,222 · Food and Beverage: $2,114 · Consulting Fee: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,222.20 |
| Food and Beverage | $2,113.52 |
| Consulting Fee | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $1,775.85 | 2025 | |
| Guerbet LLC | $1,180.65 | 2025 | Lipiodol |
| Penumbra, INC. | $1,153.79 | 2022 | |
| Delcath Systems | $861.03 | 2024-2025 | Hepzato Kit |
| Terumo Medical Corporation | $450.00 | 2025 | |
| Boston Scientific Corporation | $352.18 | 2021-2022 | |
| Sirtex Medical INC | $290.47 | 2023-2025 | Lava Les (Liquid Embolic System), Sir-Spheres Microspheres |
| Trisalus Life Sciences, INC. | $213.43 | 2025 | Trinav Infusion System |
| Siemens Medical Solutions USA, INC. | $146.12 | 2022 | |
| Abbott Laboratories | $14.29 | 2023 | Perclose Prostyle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chenyang Zhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.